crovalimab

Home
Ligands
crovalimab

GtoPdb Ligand ID: 12790

Synonyms: crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59

crovalimab is an approved drug (China NMPA, FDA & EMA (2024))

Comment: Crovalimab (SKY59/RG6107) is a long-acting anti-C5 recycling monoclonal antibody [2,6]. The antibody is engineered to bind C5 in a pH-dependent manner. It binds strongly to C5 in the plasma, but in the acidic conditions within the endosome the antibody-C5 immune complex dissociates. The free antibody is re-cycled and can bind more plasma C5, to provide sustained complement inhibition. The C5 released in the endosome is trafficked to the lysosome for degradation. Crovalimab is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) [5] and Lupus nephritis.

Immunopharmacology Comments
Crovalimab neutralises the biological actions of complement factor C5. It is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and Lupus nephritis.

Immunopharmacology Comments

Crovalimab neutralises the biological actions of complement factor C5. It is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and Lupus nephritis.